FDG vs PSMA PET for Prostate Cancer: Which to Choose When
Share
For most cancers, FDG PET-CT is the default tracer. Prostate cancer is one of the exceptions. The biology of typical prostate adenocarcinoma — slow growth, fatty acid metabolism, low glucose uptake — defeats FDG and forced the field to develop a different tracer: PSMA-targeting agents that bind a membrane protein specific to prostate cells. This article explains when each is right, what the published sensitivity looks like at different PSA levels, and what international patients pay for either scan.
Why FDG Underperforms in Prostate Cancer
Most prostate adenocarcinomas are well-differentiated and grow slowly. Their energy source is largely fatty acids (via the lipogenic pathway), not glucose. Glucose transporter expression in prostate cancer cells is typically low.
The clinical implication: FDG PET-CT sensitivity for hormone-sensitive prostate cancer at PSA <2 is approximately 20–30%. At PSA <0.5 (early biochemical recurrence), FDG sensitivity drops further to under 10%. This is essentially useless for the most common clinical scenario — locating recurrent disease at low PSA after primary treatment.
FDG does work in two specific prostate cancer scenarios:
- Castration-resistant aggressive disease — when the cancer dedifferentiates, glucose metabolism reactivates and FDG uptake rises
- Treatment-induced neuroendocrine prostate cancer — small cell-like variant after long-term hormonal therapy
In both cases, FDG-avid disease at the same site PSMA was previously avid signals biological transformation requiring different treatment.
PSMA: The Prostate-Specific Tracer
Prostate-Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein expressed at 100–1000× higher levels on prostate cancer cells than on normal prostate or other tissues. This dramatic differential makes PSMA an exceptional imaging target.
Modern PSMA PET tracers:
- Ga-68 PSMA-11 — first widely available; 68-minute half-life requires onsite Ga-68 generator
- F-18 DCFPyL (PYLARIFY) — FDA-approved 2021; 110-minute half-life allows central production and shipping
- F-18 PSMA-1007 — European alternative; minimal urinary excretion (advantage for pelvic imaging)
- Cu-64 PSMA — emerging long half-life option
For practical purposes, the choice between Ga-68 and F-18 PSMA is logistic, not diagnostic — both are excellent. F-18 variants are easier to schedule because the tracer ships from a central pharmacy.
Sensitivity by PSA Level (0.5, 1, 2, 5 ng/mL)
Detection rates after radical prostatectomy with rising PSA, from published meta-analyses:
| PSA level (ng/mL) | PSMA PET detection rate | FDG PET detection rate |
|---|---|---|
| 0.2–0.5 | 35–50% | <10% |
| 0.5–1.0 | 55–70% | ~10–15% |
| 1.0–2.0 | 80–90% | 15–25% |
| 2.0–5.0 | 90–95% | 25–40% |
| 5.0+ | 95%+ | 40–60% |
These detection rates apply to biochemical recurrence after surgery. After primary radiation, the curves shift slightly because PSA nadir is higher than post-surgery.
Initial Staging vs Biochemical Recurrence
Two distinct clinical scenarios:
Initial staging (newly diagnosed prostate cancer with intermediate or high-risk features):
- PSMA PET-CT detects nodal and distant metastases missed by conventional CT and bone scan
- Changes management in 10–25% of cases (some patients reclassified as metastatic; some patients spared aggressive local therapy)
- Now standard of care at top US, UK, EU, and Asian academic centers
Biochemical recurrence (rising PSA after primary treatment):
- PSMA PET identifies the site of recurrence — local, nodal, bone, or visceral
- Allows targeted salvage radiation if disease is isolated
- Critical decision point: confined oligometastatic disease may benefit from focal treatment; widespread disease drives systemic therapy
For staging decisions on a newly diagnosed prostate cancer, our team can help.
Cost Comparison: FDG vs PSMA Globally
| Country | FDG PET (cash) | PSMA PET (cash) |
|---|---|---|
| United States | $3,500–5,500 | $5,000–7,500 |
| United Kingdom (private) | £1,500–2,800 | £2,500–4,500 |
| Hong Kong | HKD 12,000–18,000 | HKD 18,000–28,000 |
| Singapore | SGD 3,000–4,500 | SGD 4,500–6,500 |
| Japan | JPY 200,000–280,000 | JPY 250,000–350,000 |
| Mainland China | ¥5,000–8,000 | ¥10,000–15,000 |
| India | INR 15,000–25,000 | INR 45,000–75,000 |
Mainland China prices are among the lowest globally for both scans. Top centers (PUMC Beijing, Fudan SCC, Ruijin Shanghai, Sun Yat-sen Cancer Center Guangzhou) have onsite Ga-68 generators or accept F-18 PSMA shipments from central pharmacies.
Choline PET as a Third Option
Choline PET (C-11 choline or F-18 fluorocholine) was the workhorse for prostate cancer imaging in the 2000s, before PSMA. It targets choline kinase upregulation in prostate cancer cells.
Relative to PSMA:
- Sensitivity at low PSA: choline ~30% at PSA 1.0 vs PSMA ~70%
- Sensitivity at higher PSA: choline ~85% at PSA 2.0 vs PSMA ~90%
- Specificity: similar, both high
- Availability: more limited now that PSMA has supplanted it
Where PSMA is unavailable or for specific salvage radiation planning, choline still has a role. Cost runs ¥8,000–12,000 in China.
Theranostic Treatment Planning with PSMA
Theranostics = "therapy + diagnostics." The same PSMA-targeting molecule used for imaging can be paired with a beta-emitter (Lu-177) for treatment of metastatic castration-resistant prostate cancer. This is Pluvicto (Lu-177 PSMA-617), approved in the US and EU.
The clinical workflow:
- PSMA PET imaging confirms PSMA expression in tumors (must be PSMA-positive)
- Treatment infusion every 6 weeks for up to 6 cycles
- Imaging response assessment with repeat PSMA PET
This is reshaping late-line prostate cancer treatment. Patient selection by imaging is essential — patients whose tumors are PSMA-negative (often dedifferentiated or neuroendocrine) will not benefit.
Lu-177 PSMA-617 (Pluvicto) is now available in China at select centers — Fudan SCC Shanghai, Sun Yat-sen Cancer Center, PUMC Beijing — at lower cost than US ($25,000+ per cycle in US vs ¥80,000–150,000 in China cash).
Prostate PET Imaging Availability in China
Top Chinese centers for prostate PET imaging:
- PUMC Beijing — both FDG and Ga-68 PSMA; strong urology integration
- Fudan Shanghai Cancer Center — full PSMA program including theranostics (Lu-177)
- Sun Yat-sen Cancer Center Guangzhou — full PSMA, regional referral center
- Ruijin Hospital Shanghai — Ga-68 PSMA, urology multidisciplinary
- HKU-Shenzhen Hospital — F-18 PSMA, easy access from Hong Kong
- West China Hospital Chengdu — Ga-68 PSMA, southwestern referral
International patients typically book 1–2 weeks in advance. Same-week appointments are sometimes available.
Frequently Asked Questions
My oncologist ordered FDG PET. Should I ask for PSMA instead?
For prostate cancer staging or biochemical recurrence at low PSA, PSMA is significantly more sensitive. Discuss with your oncologist before the scan. Some centers default to FDG out of habit or for insurance reasons; PSMA is worth requesting when available.
Does PSMA detect every prostate cancer?
No. Roughly 5–10% of prostate cancers are PSMA-low or PSMA-negative — particularly neuroendocrine-differentiated, treatment-induced small cell variants, and some aggressive primary tumors. FDG complements PSMA in suspected dedifferentiated disease.
Can I have both scans?
Yes. For complex cases (high-risk primary, aggressive treatment-resistant recurrence), a dual PSMA + FDG protocol provides the most complete picture. Cost is higher because it is two separate scans.
Is PSMA covered by insurance in the US?
Medicare and most major commercial insurers now cover PSMA PET (Ga-68 PSMA-11 and F-18 DCFPyL) for confirmed prostate cancer staging or biochemical recurrence. Prior authorization may be required.
Why is F-18 PSMA-1007 not approved in the US?
F-18 PSMA-1007 is approved in Europe but uses a different formulation than the US FDA-approved DCFPyL. The differences are pharmacokinetic — both work, but each country has its own approved tracer.
Is the Lu-177 PSMA treatment available outside the US?
Yes — Europe, Australia, China, and India all have growing programs. China-based treatment is typically 30–50% the US cash cost.
Need Help Booking?
SinoCareLink can pre-book PSMA or FDG PET-CT at a top Chinese cancer center, arrange Lu-177 PSMA treatment if indicated, coordinate urology consults, translate reports, and arrange airport pickup. Contact us for a free consultation.